FDA Public Information Strategy Is “Dangerous” And “Imprecise” – AEI Fellow
Executive Summary
FDA's increasing reliance on public health advisories to convey drug safety information is "dangerous" because the messages do not target the appropriate audience, American Enterprise Institute Resident Fellow Scott Gottlieb said
You may also be interested in...
Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?
Conventional antipsychotic medications should not be prescribed as replacements for atypical products despite an FDA public health advisory about the newer agents because conventional medications appear to have higher mortality in elderly patients, an article in the Dec. 1 New England Journal of Medicine concludes
Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?
Conventional antipsychotic medications should not be prescribed as replacements for atypical products despite an FDA public health advisory about the newer agents because conventional medications appear to have higher mortality in elderly patients, an article in the Dec. 1 New England Journal of Medicine concludes
FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues
FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses